HealthTech180
  • Home
  • Activities
  • Our Team
  • Contact Us
Select Page

FDA grants Breakthrough Therapy Designation to psilocybin program for major depressive disorder

by admin | Nov 25, 2019 | FDA

Usona Institute has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for psilocybin in the treatmentof major depressive disorder (MDD). Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an...
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.

Categories

Follow Us

Tags

AI Alzheimer antibodies bacteria binx health Biosimilar Blood Filter Cancer cardiovascular cell therapy CE Mark clinical trial colorectal cancer Diagnostics Digital Health Drug Discovery ExThera Medical FDA FDA approval funding fundraising glycosylation Halodoc HIV Innovation Licensing M&A medical device medtech microbial microbial DNA microbial RNA microbiome Neuro Novartis pharma Pharming Prescient Metabiomics robots software Therapeutics Therapy USA VIrology women health

Home
Activities
Our Team
Contact Us

         contact@healthtech180.com

Privacy Policy

© 2022 HealthTech180 Advisory S.L.